Patents by Inventor Reiner L. Gentz

Reiner L. Gentz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Death domain containing receptor 4
    Publication number: 20040136950
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
    Type: Application
    Filed: August 27, 2003
    Publication date: July 15, 2004
    Applicants: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz
  • Death domain containing receptor 5
    Publication number: 20040136951
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which maybe agonists and/or antagonists of DR5 activity.
    Type: Application
    Filed: August 27, 2003
    Publication date: July 15, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Death domain containing receptors
    Patent number: 6759513
    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: July 6, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Reiner L. Gentz, Patrick J. Dillon
  • I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD 95 induced apoptosis
    Publication number: 20040121387
    Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.
    Type: Application
    Filed: November 17, 2003
    Publication date: June 24, 2004
    Applicants: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, Vishva M. Dixit, Reiner L. Gentz, Joseph J. Kenny
  • Human extracellular matrix-1
    Publication number: 20040110677
    Abstract: A human ECM-1 polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for stimulating the differentiation in growth of osteoblasts and osteoclasts, which may be used to promote the healing of bone fractures and de novo bone formation, for osteoporosis, for and to promote angiogenesis. Antagonists to the polypeptide of the present invention are also disclosed which may be utilized to treat osteodystrophy, osteohypertrophy, osteoma, osteoblastoma and cancers. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention.
    Type: Application
    Filed: May 12, 2003
    Publication date: June 10, 2004
    Applicants: Human Genome Sciences, Inc., University of Antwerp
    Inventors: Jian Ni, Ping Feng, Patrick J. Dillon, Reiner L. Gentz, Joseph Merregaert, Patrick Smits
  • Cytostatin II
    Patent number: 6746674
    Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: June 8, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Reiner L. Gentz
  • Death domain containing receptor 5
    Patent number: 6743625
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: June 1, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Pancreas-derived plasminogen activator inhibitor
    Publication number: 20040086978
    Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions and diagnostic methods for detecting pathologic disorders.
    Type: Application
    Filed: July 29, 2003
    Publication date: May 6, 2004
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben, Y. Eric Shi
  • 5-Lipoxygenase-activating protein II
    Publication number: 20040086952
    Abstract: Disclosed is a human FLAP II polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques. Further, antagonists against such polypeptide are disclosed. Such antagonists may be used for therapeutic proposes, for example, for treating inflamation, bronchial asthma and may also be used as gastric cytoprotective agents and to treat human glomerulonephritis. Diagnostic assays for identifying mutations in nucleic acid sequences encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Application
    Filed: July 28, 2003
    Publication date: May 6, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Robert Fleischmann
  • Keratinocyte growth factor-2 formulations
    Publication number: 20040063639
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Application
    Filed: October 30, 2003
    Publication date: April 1, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Death domain containing receptors
    Patent number: 6713061
    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.
    Type: Grant
    Filed: April 21, 2000
    Date of Patent: March 30, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Guo-Liang Yu, Jian Ni, Vishva M. Dixit, Reiner L. Gentz, Patrick J. Dillon
  • Keratinocyte growth factor-2
    Patent number: 6693077
    Abstract: This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is a Keratinocyte Growth Factor, sometimes hereinafter referred to as “KGF-2” also formerly known as Fibroblast Growth Factor 12 (FGF-12). This invention further relates to the therapeutic use of KGF-2 to promote or accelerate wound healing. This invention also relates to novel mutant forms of KGF-2 that show enhanced activity, increased stability, higher yield or better solubility.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: February 17, 2004
    Assignee: Human Genome Sciences, Inc.
    Inventors: Steven M. Ruben, Pablo Jimenez, D. Roxanne Duan, Mark A. Rampy, Donna Mendrick, Jun Zhang, Jian NI, Paul A. Moore, Timothy A. Coleman, Joachim R. Gruber, Patrick J. Dillon, Reiner L. Gentz
  • Method of purifying protein from inclusion bodies
    Publication number: 20040024186
    Abstract: The present invention relates to processes for the purification of proteins. More specifically, methods for solubilizing and purifying proteins expressed in an insoluble form using low concentrations of chaotropic agents, such as guanidine salts, are provided. Also provided are methods for refolding proteins solubilized according to the present invention.
    Type: Application
    Filed: July 31, 2003
    Publication date: February 5, 2004
    Applicant: Human Genome Sciences, Inc.
    Inventors: Yuling Li, Mark Oelkuct, Reiner L. Gentz
  • Tumor necrosis factor receptors 6 alpha & 6 beta
    Publication number: 20040013664
    Abstract: The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6&agr; & -6&bgr; proteins. TNFR-6&agr; & -6&bgr; polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6&agr; & -6&bgr; activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
    Type: Application
    Filed: April 18, 2003
    Publication date: January 22, 2004
    Inventors: Reiner L. Gentz, Guo-Liang Yu, Jian Ni, Reinhard Ebner, Ping Feng, Steven M. Ruben
  • I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD-95 induced apoptosis
    Patent number: 6680171
    Abstract: The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of INFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE-2 protein. I-FLICE-1 or I-FLICE-2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of I-FLICE-1 or I-FLICE-2 activity. Also provided are therapeutic methods for treating diseases and disorders associated with apoptosis.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: January 20, 2004
    Assignees: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, Vishva M. Dixit, Reiner L. Gentz, Joseph J. Kenny
  • T1 receptor-like ligand II polypeptides
    Patent number: 6667032
    Abstract: The present invention concerns a novel T1R-like ligand II protein. In particular, isolated nucleic acid molecules are provided encoding the T1R-like ligand II protein. T1R-like ligand II polypeptides are also provided, as are recombinant vectors and host cells for expressing the same.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: December 23, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben
  • Human tumor necrosis factor receptor TR9
    Patent number: 6667390
    Abstract: The present invention relates to a novel member of the tumor necrosis factor family of receptors. In particular, isolated nucleic acid molecules are provided encoding the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR9 receptor activity.
    Type: Grant
    Filed: January 10, 2001
    Date of Patent: December 23, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Guo-Liang Yu, Ping Fan, Reiner L. Gentz
  • 28 human secreted proteins
    Publication number: 20030225009
    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
    Type: Application
    Filed: January 30, 2002
    Publication date: December 4, 2003
    Inventors: Craig A. Rosen, Steven M. Ruben, Yi Li, ZhiZhen Zeng, Hla Kyaw, Carrie L. Fischer, Haodong Li, Daniel R. Soppet, Reiner L. Gentz, Ying-Fei Wei, Paul A. Moore, Paul E. Young, John M. Greene, Ann M. Ferrie, Gregg A. Hastings
  • Keratinocyte growth factor-2 formulations
    Patent number: 6653284
    Abstract: The invention is directed to liquid and lyophilized forms of Keratinocyte Growth Factor-2 (KGF-2) and derivatives thereof. This invention further relates to the formulation of KGF-2 for therapeutic use, for example, to promote or accelerate wound healing.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: November 25, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Reiner L. Gentz, Arvind Chopra, Parveen Kaushal, Thomas Spitznagel, Edward Unsworth, Fazal Khan
  • Pancreas-derived plasminogen activator inhibitor
    Patent number: 6649738
    Abstract: The present invention relates to a novel member of the plasminogen activator inhibitor protein family. In particular, isolated nucleic acid molecules are provided encoding the pancreas-derived plasminogen activator inhibitor protein. Pancreas-derived plasminogen activator inhibitor polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to methods for treating physiologic and pathologic disease conditions, including breast cancer, and diagnostic methods for detecting pathologic disorders.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: November 18, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Steven M. Ruben